Search results
New hope for those living with Sickle Cell Disorder thanks to experimental gene treatment
WSB-TV 2 Atlanta· 6 days agoThe treatment is a gene cell therapy recently approved by the U.S. Food and Drug Administration. For...
Woman Thought Baby's Facial Feature Was Trait from Dad, Then Realizes It's Symptom of Childhood...
People via Yahoo News· 23 hours agoFollowing a series of tests and a "week of nerves," Lydia...New Orleans-based genetics specialist,...
Risk of secondary cancers after CAR-T cell therapy low, according to large study
Medical Xpress· 2 days agoA large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 4 hours agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....
Study Elucidates Skin Signs of VEXAS Syndrome
Medscape· 11 hours agoSkin manifestations are common in the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome and present early in the disease course....
Solving RLS: Largest Genetic Study to Date May Help
Medscape· 11 hours agoFor decades, scientists have been trying to unravel the mysteries of restless legs syndrome (RLS), a poorly understood and underdiagnosed neurological ...
Sernova Provides Update on Public Offering
NewMediaWire via Yahoo Finance· 2 days agoLONDON, Ontario and BOSTON, Massachusetts - (NewMediaWire) - June 12, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage...
2 Healthcare Stocks to Buy Hand Over Fist in June
The Motley Fool via AOL· 2 days agoCF is a rare genetic disorder that causes damage to various internal organs. Vertex's leadership...innovating, as evidenced by positive phase 3 data for...
FDA Expands Repotrectinib Label
Medscape· 1 day agoThe new accelerated approval for the TKI was based on the overall response rate in 48 patients.
A Drug to Slow Alzheimer’s Is Finally Available. How Are Patients Faring?
New York Times· 4 days agoAs the F.D.A. considers a new Alzheimer’s medication, we asked experts how the rollout of a similar...